Privacy Policy
Signals Blog

Contributors

Categories

The Canadian regulatory system for cell and gene therapies

Aileen J. Zhou brings over a decade of experience in biotech and medical device regulatory affairs. She is an active member and contributing author of the Regulatory Affairs Professional Society (RAPS) and Alliance for Regenerative Medicine’s Regulatory and CMC...

A foray into the future: Predictions for the year 2050

In part 1 of this feature marking the 10-year anniversary of Signals, we got to know the people behind the posts a little better. Now, we’re looking to the future of regenerative medicine and science with the help of our contributors. In this post, bloggers Lyla...

Comparing two snapshots of RM taken a decade apart

When Signals first burst onto the scene in 2012, the potential of the regenerative medicine industry still hadn’t set in for many. When the Alliance for Regenerative Medicine (ARM) published its first state of the industry report in 2012, the ARM chairman at the time,...

Right Turn: Looking back on 10 amazing years at Signals

This month is the 10-year anniversary of when Lisa Willemse and I launched Signals. As you would imagine, blogs come and go so 10 years is a significant milestone. It is also my 10-year anniversary at CCRM and when I was introduced to the regenerative medicine field....

Genetically engineering cures for sickle cell disease

If I were to ask you to think of a genetic disease that should be a priority for gene therapy research, you might say breast cancer, Huntington’s, or cystic fibrosis. And these are all great candidates. But I’d say you’re missing a big one. Sickle cell disease (SCD)...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!